Pharmaceutical

EC upgrades approval for J&J’s Rybrevant/chemotherapy combination in NSCLC

Rybrevant has been granted a Type II approval extension to treat NSCLC with EGFR mutations following the failure of TKI therapy.

Aug 29, 2024 - 04:00
EC upgrades approval for J&J’s Rybrevant/chemotherapy combination in NSCLC
Rybrevant has been granted a Type II approval extension to treat NSCLC with EGFR mutations following the failure of TKI therapy.
Read the original article

Tags:

Previous Article

Eli Lilly’s Zepbound to be issued in single-dose vials for self-payers

Next Article

Singapore approves mpox vaccine as it adds border infection checks

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

When confronted with mysterious illness in college, ‘Chronically Catherine’ started writing

When confronted with mysterious illness in college, ‘Ch...

Apr 5, 2023

Partnerships are key to driving digital healthcare transformation in US, say experts 

Partnerships are key to driving digital healthcare tran...

Apr 3, 2024

Supreme Court strikes down use of affirmative action, a blow to efforts to diversify medical schools

Supreme Court strikes down use of affirmative action, a...

Jun 30, 2023